Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Bar-Or A, et al. Among authors: leutmezer f. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. Mult Scler. 2022. PMID: 34605319 Free PMC article. Clinical Trial.
Month-of-birth-effect in multiple sclerosis in Austria.
Walleczek NK, Frommlet F, Bsteh G, Eggers C, Rauschka H, Koppi S, Assar H, Ehling R, Birkl C, Salhofer-Polanyi S, Baumgartner A, Blechinger S, Buchinger D, Sellner J, Kraus J, Moser H, Mayr M, Guger M, Rathmaier S, Raber B, Liendl H, Hiller MS, Parigger S, Morgenstern G, Kempf I, Spiss HK, Meister B, Heine M, Cisar A, Bachler H, Khalil M, Fuchs S, Enzinger C, Fazekas F, Leutmezer F, Berger T, Kristoferitsch W, Aboulenein-Djamshidian F. Walleczek NK, et al. Among authors: leutmezer f. Mult Scler. 2019 Dec;25(14):1870-1877. doi: 10.1177/1352458518810924. Epub 2018 Nov 22. Mult Scler. 2019. PMID: 30463473
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Bsteh G, Dürauer S, Assar H, Hegen H, Heschl B, Leutmezer F, Pauli FD, Gradl C, Traxler G, Zulehner G, Rommer P, Wipfler P, Guger M, Höftberger R, Enzinger C, Berger T. Bsteh G, et al. Among authors: leutmezer f. Mult Scler. 2021 Dec;27(14):2209-2218. doi: 10.1177/13524585211049391. Epub 2021 Oct 1. Mult Scler. 2021. PMID: 34595968 Free PMC article.
Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
Bsteh G, Hegen H, Berek K, Altmann P, Auer M, Di Pauli F, Haider L, Leutmezer F, Rommer P, Walchhofer LM, Wurth S, Zinganell A, Deisenhammer F, Berger T. Bsteh G, et al. Among authors: leutmezer f. Mult Scler. 2022 Sep;28(10):1541-1552. doi: 10.1177/13524585221079744. Epub 2022 Mar 12. Mult Scler. 2022. PMID: 35282741
Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication - a retrospective multicentre study.
Di Pauli F, Riedl K, Hegen H, Auer M, Berek K, Krajnc N, Leutmezer F, Zinganell A, Berger T, Deisenhammer F, Bsteh G. Di Pauli F, et al. Among authors: leutmezer f. Mult Scler Relat Disord. 2022 Jul;63:103810. doi: 10.1016/j.msard.2022.103810. Epub 2022 Apr 20. Mult Scler Relat Disord. 2022. PMID: 35477127 Free article.
Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
Bsteh G, Hegen H, Krajnc N, Föttinger F, Altmann P, Auer M, Berek K, Kornek B, Leutmezer F, Macher S, Monschein T, Ponleitner M, Rommer P, Schmied C, Zebenholzer K, Zulehner G, Zrzavy T, Deisenhammer F, Di Pauli F, Pemp B, Berger T. Bsteh G, et al. Among authors: leutmezer f. Mult Scler. 2024 Aug;30(9):1128-1138. doi: 10.1177/13524585241267257. Epub 2024 Aug 7. Mult Scler. 2024. PMID: 39109593 Free article.
Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis.
Salhofer-Polanyi S, Windt J, Sumper H, Grill H, Essmeister M, Diermayr G, Zebenholzer K, Leutmezer F, Zulehner G, Vass K, Asenbaum-Nan S. Salhofer-Polanyi S, et al. Among authors: leutmezer f. NeuroRehabilitation. 2013;33(2):285-92. doi: 10.3233/NRE-130956. NeuroRehabilitation. 2013. PMID: 23949063 Clinical Trial.
What to expect after natalizumab cessation in a real-life setting.
Salhofer-Polanyi S, Baumgartner A, Kraus J, Maida E, Schmied M, Leutmezer F. Salhofer-Polanyi S, et al. Among authors: leutmezer f. Acta Neurol Scand. 2014 Aug;130(2):97-102. doi: 10.1111/ane.12250. Epub 2014 Apr 10. Acta Neurol Scand. 2014. PMID: 24720783
142 results